Revolution Medicines (NASDAQ:RVMD) COO Sells 4,967 Shares of Stock

Key Points

• Revolution Medicines COO Margaret Horn sold 4,967 shares at an average price of $199.24, generating approximately $989,625. The sale covered tax-withholding obligations, and she retained 149,680 shares.
• RVMD shares fell 3.0% to $190.95, while the company reported a quarterly EPS loss of $3.06—worse than analysts’ expected loss of $2.04.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $226.17; institutional investors own 94.34% of the stock.

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) COO Margaret Horn sold 4,967 shares of the stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total transaction of $989,625.08. Following the transaction, the chief operating officer directly owned 149,680 shares of the company's stock, valued at $29,822,243.20. The trade was a 3.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Revolution Medicines Trading Down 3.0%

NASDAQ RVMD traded down $5.99 during trading on Friday, hitting $190.95. The stock had a trading volume of 5,937,950 shares, compared to its average volume of 2,930,039. Revolution Medicines, Inc. has a twelve month low of $42.18 and a twelve month high of $224.31. The firm has a 50 day moving average price of $199.49 and a 200 day moving average price of $159.35. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $40.93 billion, a PE ratio of -21.65 and a beta of 1.40.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing analysts' consensus estimates of ($2.04) by ($1.02). During the same quarter last year, the business posted ($1.31) EPS. As a group, equities research analysts forecast that Revolution Medicines, Inc. will post -8.87 earnings per share for the current year.

Hedge Funds Weigh In On Revolution Medicines

A number of hedge funds have recently made changes to their positions in RVMD. Contravisory Investment Management Inc. acquired a new stake in shares of Revolution Medicines during the 2nd quarter worth $32,000. ABS Investment Management LLC acquired a new stake in Revolution Medicines during the second quarter worth about $337,104,000. Johnson Financial Group Inc. purchased a new position in shares of Revolution Medicines in the 2nd quarter worth about $37,000. Northwestern Mutual Wealth Management Co. purchased a new position in Revolution Medicines in the second quarter valued at approximately $41,000. Finally, Silvant Capital Management LLC purchased a new stake in shares of Revolution Medicines in the second quarter worth about $41,000. Institutional investors and hedge funds own 94.34% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on RVMD shares. Needham & Company LLC raised their price target on Revolution Medicines from $240.00 to $275.00 and gave the stock a "buy" rating in a research note on Monday, August 31st. Wolfe Research reiterated an "outperform" rating and set a $220.00 price target on shares of Revolution Medicines in a research note on Monday, August 10th. Oppenheimer increased their price objective on Revolution Medicines from $230.00 to $260.00 and gave the stock an "outperform" rating in a research report on Thursday, August 27th. Stifel Nicolaus increased their target price on shares of Revolution Medicines from $215.00 to $230.00 and gave the company a "buy" rating in a report on Wednesday, September 9th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Revolution Medicines in a research note on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $226.17.

Revolution Medicines Company Profile

Revolution Medicines, Inc is a clinical-stage biotechnology company focused on developing targeted treatments for cancer. The company specializes in therapies designed to inhibit oncogenic RAS signaling, a pathway involved in many difficult-to-treat cancers, including tumors driven by KRAS mutations.

Its pipeline includes investigational RAS(ON) inhibitors intended to target active forms of RAS proteins. Key programs have included daraxonrasib (RMC-6236), an oral inhibitor being studied in cancers with a range of RAS mutations, as well as mutation-selective programs such as RMC-9805 for KRAS G12D and RMC-6291 for KRAS G12C.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.